Chang-Lian Lu

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Non-small cell lung cancer (NSCLC) patients who do initially respond to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) may eventually develop resistance, which may at least partly be due to the acquisition of a secondary EGFR mutation (T790M). Additionally, it has been found that KRAS mutations may serve as poor prognostic(More)
  • 1